Literature DB >> 1874797

Genetics of the malignant progression of astrocytoma.

T Mikkelsen1, J G Cairncross, W K Cavenee.   

Abstract

The tendency of human cancers to progress towards a more malignant state over time is a well described biological phenomenon. Recent investigations elucidating the genetic nature of malignancy and the possible mechanisms responsible for this evolution have suggested that a sequential pathway may exist whereby a cell population accumulates a nested set of genetic aberrations which endow it with the ability to overwhelm other populations and dominate the tumor. Human astrocytomas are a dramatic case in point, where specific genetic events of amplification and deletion are seemingly related to the stages of malignancy. The identification of these aberrations represents the first stage in the dissection of the temporal process of this cancer. Its augmentation with functional analyses will likely allow a fuller genetic description of in vivo transformation.

Entities:  

Mesh:

Year:  1991        PMID: 1874797     DOI: 10.1002/jcb.240460103

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Apoptosis and p53 expression in human gliomas.

Authors:  L Sipos; Z Szegedi; I Fedorcsák; D Afra; B Szende
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Karyotype analyses of 20 human glioma cell lines.

Authors:  M Westphal; M Hänsel; W Hamel; R Kunzmann; F Hölzel
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

3.  Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas.

Authors:  A M Yahanda; J M Bruner; L A Donehower; R S Morrison
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

4.  The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event.

Authors:  A B Stoler; F Stenback; A Balmain
Journal:  J Cell Biol       Date:  1993-09       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.